Clinical Trial Detail

NCT ID NCT03098160
Title Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Recruitment Unknown status
Gender both
Phase Phase I
Variant Requirements No
Sponsors Threshold Pharmaceuticals
Indications

head and neck squamous cell carcinoma

prostate cancer

melanoma

pancreatic cancer

Therapies

Evofosfamide + Ipilimumab

Age Groups: senior adult

No variant requirements are available.